Investigating PASK as a target for treating ALS and frontotemporal dementia
Official title: PASK-regulated genes and proteins as therapeutic targets for ALS and FTD
Funded at University of Utah · NIH-10872746 · Data updated 2026-11-12
This study is looking at how a protein called PASK affects diseases like ALS and frontotemporal dementia, with the hope of finding new ways to treat these conditions and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | September 19, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $752,319 |
| NIH project number | 1R01NS137233-01 |
| Project ID | NIH-10872746 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with ALS or frontotemporal dementia.
✕Less likely to help
Patients with other forms of dementia unrelated to ALS or FTD may not receive benefit from this research.
What this research studies
This research focuses on understanding how the PASK protein influences neurodegenerative diseases like ALS and frontotemporal dementia (FTD). By studying the relationship between PASK and other proteins involved in cellular processes, the researchers aim to identify new therapeutic targets. The approach involves using genetic techniques and specific inhibitors to manipulate PASK levels in cell cultures and animal models, which may lead to improved cellular function and reduced disease symptoms. Patients may benefit from potential new treatments that target the underlying mechanisms of these conditions.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that slow down or halt the progression of ALS and FTD.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in neurodegenerative diseases, suggesting potential for success in this approach.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Scoles, Daniel R — University of Utah
- Study coordinator: Scoles, Daniel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.